2-氯-4-嘧啶甲酸 | 149849-92-3

• 物质功能分类: 化学试剂 - 有机试剂 - 脲
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氯-4-嘧啶甲酸
• 中文别名: 2-氯嘧啶-4-甲酸
• 英文名称: 2-chloropyrimidine-4-carboxylic acid
• CAS: 149849-92-3
• 化学式: C₅H₃ClN₂O₂
• mdl: MFCD06739041
• 分子量: 158.544
• InChiKey: YMDSUQSBJRDYLI-UHFFFAOYSA-N

物化性质

• 沸点：
  411.4±18.0 °C(Predicted)
• 密度：
  1.579

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S22,S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933599090
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloropyrimidine-4-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloropyrimidine-4-carboxylic acid
CAS number: 149849-92-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H3ClN2O2
Molecular weight: 158.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用

2-氯嘧啶-4-甲酸可以用于治疗高磷血症，并且是合成苯磺酰胺吡唑激酶抑制剂的关键中间体。

制备

将2-氯-4-甲基嘧啶盐酸盐与三氯氧磷进行脱盐酸反应，分离得到2-氯-4-甲基嘧啶。具体操作为：先将三氯化磷和2-氯-4-甲基嘧啶盐酸盐混合并加热至80℃，随后滴加三乙胺进行脱盐酸反应。待反应结束后降温，并将反应物倒入碎冰中以分解三氯氧磷。接着加入二氯乙烷分散体系，并用氢氧化钠溶液调节pH值为6～7。之后，加入乙酸乙酯进行萃取分离并回收有机相，对回收的有机相依次进行脱色、抽滤和蒸发浓缩处理，最终得到2-氯-4-甲基嘧啶。

反应信息

• 作为反应物：
  描述：

  2-氯-4-嘧啶甲酸 在 甲醇 、 sodium tetrahydroborate 、 N,N-二甲基甲酰胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 6.0h， 生成 (2-氯嘧啶-4-基)甲醇
  参考文献：
  名称：

  [EN] HETEROCYCLIC AMIDES AS KINASE INHIBITORS
  [FR] AMIDES HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASE

  摘要：

  揭示了具有以下公式的化合物：其中R1和R2如本文所定义，并且揭示了制备和使用这些化合物的方法。

  公开号：

  WO2018092089A1
• 作为产物：
  描述：

  2-氯-4-甲基嘧啶 在 N-羟基邻苯二甲酰亚胺 、 二乙二醇二甲醚 、 氧气 、 cobalt(II) acetate 、 manganese(II) acetate 作用下， 以 溶剂黄146 为溶剂， 反应 2.0h， 以80.8%的产率得到2-氯-4-嘧啶甲酸
  参考文献：
  名称：

  2-氯嘧啶-4-甲酸类化合物的连续性合成方法

  摘要：

  本发明提供了一种2‑氯嘧啶‑4‑甲酸类化合物的连续性合成方法。2‑氯嘧啶‑4‑甲酸类化合物具有式I所示结构：式I式I中，R1和R2分别独立地选自氢、烷氧基、芳基、苄基或氟；合成方法包括以下步骤：S1，在非贵金属催化剂的作用下，将化合物A与甲基格氏试剂B进行连续甲基化反应，得到化合物C；化合物A为，化合物C为，R1和R2具有与前文相同定义，非贵金属催化剂为铁盐、钴盐、镍盐中的一种或多种；S2，将化合物C在氧气、氧化催化剂及添加剂的作用下进行连续氧化反应，得到2‑氯嘧啶‑4‑甲酸类化合物。采用本发明提供的工艺合成2‑氯嘧啶‑4‑甲酸类化合物，能够兼顾成本、收率、环保性等方面。

  公开号：

  CN110642789B

文献信息

• [EN] AZOLE COMPOUNDS AS PIM INHIBITORS<br/>[FR] COMPOSÉS D'AZOLE UTILISÉS EN TANT QU'INHIBITEURS DES PIM
  申请人：AMGEN INC

  公开号：WO2012129338A1

  公开（公告）日：2012-09-27

  The invention relates to bicyclic compounds of formulas I and Ia, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

  该发明涉及公式I和Ia的双环化合物及其盐。在某些实施例中，该发明涉及Pim-1和/或Pim-2和/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，该发明涉及包含本文所披露的化合物的药物组合物，以及它们在预防和治疗Pim激酶相关疾病和病症，尤其是癌症中的用途。
• Suzuki–Miyaura cross-coupling reaction of aryl and heteroaryl pinacol boronates for the synthesis of 2-substituted pyrimidines
  作者：Shigehiro Asano、Seiji Kamioka、Yoshiaki Isobe

  DOI：10.1016/j.tet.2011.10.057

  日期：2012.1

  Suzuki–Miyaura cross-coupling reaction with 2-heteroarylboronic acids is generally challenging due to these acids easy decomposition. To overcome this problem, we developed a coupling method that uses 2-heteroaryl pinacol boronates in the presence of 1.0 mol % Pd(OAc)2 and 2.0 mol % S-Phos with 4 equiv amount of LiOH in dioxane and H2O at 80 °C for 30 min. This developed method allowed for the synthesis

  由于这些酸易于分解，因此与2-杂芳基硼酸的铃木-宫浦交叉偶联反应通常具有挑战性。为克服此问题，我们开发了一种偶合方法，该方法在1.0 mol％Pd（OAc）2和2.0 mol％S-Phos的存在下，在80％的二恶烷和H 2 O中于80摩尔下使用2-杂芳基频哪醇硼酸酯°C 30分钟。这种发达的方法允许从2-氯嘧啶基衍生物高产率地合成各种各样的2-杂芳基嘧啶，并且还可以用于由杂芳基氯化物制备各种联芳基衍生物。
• [EN] IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES<br/>[FR] DÉRIVÉS D'IMIDAZOPYRIDINE EN TANT QU'INHIBITEURS DE TYROSINES KINASES RÉCEPTRICES
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2009150240A1

  公开（公告）日：2009-12-17

  The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

  这项发明涉及新的双环杂环衍生物化合物，包括含有该化合物的药物组合物，以及利用该化合物治疗疾病，例如癌症。
• [EN] SUBSTITUTED PIPERAZINE COMPOUNDS AND METHODS AND USE THEREOF<br/>[FR] COMPOSÉS PIPÉRAZINIQUES SUBSTITUÉS, PROCÉDÉS ET UTILISATION ASSOCIÉS
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2015169180A1

  公开（公告）日：2015-11-12

  Provided herein are novel piperazine compounds acting as selective serotonin reuptake inhibitors and/or the 5-HT1A receptor agonists. The invention also relates to the methods of preparing the compound and pharmaceutical composition, and the use of treating central nervous system dysfunction in mammals especially in humans.

  本文提供了作为选择性血清素再摄取抑制剂和/或5-HT1A受体激动剂的新型哌嗪化合物。该发明还涉及制备该化合物和药物组合物的方法，以及用于治疗哺乳动物中枢神经系统功能障碍，特别是人类的用途。
• [EN] CD38 INHIBITORS<br/>[FR] INHIBITEURS DE CD38
  申请人：MITOBRIDGE INC

  公开号：WO2021207186A1

  公开（公告）日：2021-10-14

  One embodiment of the invention is a compound represented by Formula I: or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are CD38 inhibitors, which can be used to treat a disease or condition in a subject that benefits from an increase in NAD+ or to treat a mitochondrial disorder in a subject.

  该发明的一个实施例是由化学式I表示的化合物：或其药用可接受的盐。化学式I中的变量在此处定义。化学式I的化合物是CD38抑制剂，可用于治疗需要增加NAD+的受试者的疾病或病况，或用于治疗受试者的线粒体疾病。